Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Precision BioSciences, Inc. - Common Stock (NQ:DTIL)

4.100 -0.060 (-1.44%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Precision BioSciences, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
3 Penny Stocks to Catapult You Into the Millionaires’ Club ↗
These penny stocks can deliver tremendous upside from their depressed range. Wall Street analysts can back it up! 
Via InvestorPlace
News headline image
Precision BioSciences Announces Oral Presentation of Positive ARCUS® Gene Editing Data at International Liver Congress 2023
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 33 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Precision BioSciences to Present at Upcoming June Investor Conferences
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Preview: Precision BioSciences's Earnings ↗
 
Via Benzinga
News headline image
Looking Into Precision BioSciences's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Preview: Precision BioSciences's Earnings ↗
 
Via Benzinga
News headline image
Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Provide an Update on its Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on May 31, 2023
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Participate in Upcoming Stifel Genetic Medicines Day
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at the American Society of Gene & Cell Therapy 26th Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Publication of its Preclinical In Vivo Gene Editing Abstract on Duchenne Muscular Dystrophy Program for the American Society of Gene & Cell Therapy 26th Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Report First Quarter 2023 Results on May 9, 2023
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Present Preclinical In Vivo Gene Editing Research for its ARCUS HBV Program at Upcoming Global Hepatitis Summit 2023
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Participate in Upcoming Guggenheim Healthcare Talks Conference
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  Tuesday's morning session saw 84 companies set new 52-week lows. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023 ↗
 
Via Benzinga
News headline image
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2022 Results on March 9, 2023
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Senior Leadership Promotions and Organizational Changes
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Participate in Upcoming H.C. Wainwright Cell Therapy Virtual Conference
From Precision BioSciences, Inc.
Via Business Wire
News headline image
There's a Lot of Upside For Emerging Gene-Editing Companies
These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come. 
Via MarketBeat
News headline image
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones
From Precision BioSciences
Via Business Wire
News headline image
Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate
From Precision BioSciences, Inc.
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.